Welcome to our dedicated page for Burning Rock Biotech news (Ticker: BNR), a resource for investors and traders seeking the latest updates and insights on Burning Rock Biotech stock.
Burning Rock Biotech Ltd (BNR) delivers precision oncology solutions through advanced genomic testing and cancer diagnostics. This news hub provides investors and healthcare professionals with essential updates on the company’s innovations in next-generation sequencing (NGS) technology and clinical developments.
Access authoritative reporting on BNR’s regulatory milestones, clinical study results, and strategic partnerships. The curated collection includes earnings announcements, product launch details, and progress in early cancer screening technologies. Each update is verified for clinical relevance and financial significance.
Key focus areas include therapy selection advancements for late-stage cancer patients, expansion of in-hospital testing capabilities, and developments in liquid biopsy technologies. Stay informed about BNR’s contributions to personalized cancer treatment protocols and diagnostic standardization efforts.
Bookmark this page for streamlined access to Burning Rock’s official communications. Regularly updated with validated information to support informed decision-making in oncology investments and clinical practice.
Burning Rock Biotech (NASDAQ: BNR) has announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) in China. This partnership aims to enhance diagnostic methods and enable better treatment choices for cancer patients. The collaboration will focus on developing CDx products for Bayer's precision cancer therapies. Burning Rock's CEO, Mr. Han, emphasized the commitment to global development in cancer diagnosis and treatment, aiming to set high standards and provide more effective treatment options through this partnership.
Burning Rock Biotech (NASDAQ: BNR, LSE: BNR), a precision oncology firm using next-generation sequencing (NGS) technology, announced its Q1 2024 financial results. Total revenues for the quarter were RMB125.6 million (US$17.4 million), an 11.9% decrease year-over-year (YoY). The in-hospital segment grew by 11.3%, while central laboratory and pharma research services declined by 23.0% and 29.3% respectively. Gross profit dropped by 13.2% to RMB85.7 million (US$11.9 million), and the gross margin fell to 68.2%. Operating expenses decreased by 26.4% to RMB211.5 million (US$29.3 million), driven by improved efficiency. Net loss narrowed to RMB121.5 million (US$16.8 million) from RMB185.3 million YoY. The company expects to break even by the end of 2024 based on non-GAAP measures. Cash and equivalents stood at RMB572.7 million (US$79.3 million). Additionally, the company relocated its headquarters to Guangzhou.
Burning Rock Biotech (NASDAQ: BNR; LSE: BNR) will release its unaudited financial results for Q1 2024 on May 29, 2024, before the U.S. market opens.
The company will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss the results. Interested participants should register in advance and join the call 15 minutes early.
A live and archived webcast of the call will be available on the company’s investor relations website for 12 months.
Visit the investor relations website on May 29, 2024, to access the earnings release.
Burning Rock Biotech (NASDAQ: BNR, LSE: BNR) will change the ratio of its American Depositary Shares (ADS) to Class A ordinary shares, effective May 15, 2024. The new ratio will be one ADS representing ten Class A shares, akin to a one-for-ten reverse ADS split. Certificates must be exchanged through Citibank for new ADSs, while uncertificated ADSs will be automatically adjusted. Trading on NASDAQ and LSE will continue under the symbol 'BNR' with updated security codes. Fractional new ADSs won't be issued; instead, they will be sold, and proceeds distributed to holders. The ADS price is anticipated to rise tenfold, although no guarantee is provided.
FAQ
What is the current stock price of Burning Rock Biotech (BNR)?
What is the market cap of Burning Rock Biotech (BNR)?
